Sarepta Therapeutics (AB3A) Stock Statistics & Valuation Metrics

Sarepta Therapeutics has a market cap or net worth of CHF1.57B. The enterprise value is $2.15K.

Sarepta Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Sarepta Therapeutics’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -29.03%.

The current PE Ratio of Sarepta Therapeutics is ―. Sarepta Therapeutics’s PEG ratio is 0.00777.

In the last 12 months, Sarepta Therapeutics had revenue of 2.20B and earned -713.41M in profits. Earnings per share was -7.13.

In the last 12 months, operating cash flow was -91.67M and capital expenditures -39.79M, giving a free cash flow of -131.47M billion.

Sarepta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Sarepta Therapeutics upcoming earnings date is Nov 4, 2026, After Close (Confirmed).

Sarepta Therapeutics as a current ratio of 2.32, with Debt / Equity ratio of 68.45%

In the past 12 months, Sarepta Therapeutics has paid 11.19M in taxes.

Sarepta Therapeutics EV to EBITDA ratio is -3.85, with an EV/FCF ratio of -8.11.

Sarepta Therapeutics has CHF788.49M in cash and marketable securities with CHF1.05B in debt, giving a net cash position of -CHF257.36M billion.

Gross margin is 58.56%, with operating margin of -29.92%, and net profit margin of -32.45%.

The average price target for Sarepta Therapeutics is CHF18.30, which is 11.43% higher than the current price. The consensus rating is Hold